A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.
Clinical trial NCT03966651 · COMPLETED
Trial details
- NCT number
- NCT03966651
- Sponsor
- Institut Claudius Regaud
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-17
- Primary completion
- 2024-08-08
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.